Drugs / Prolensa
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | PROLENSA | — | 2013-04-05 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05626478 Background | Jun 2023 → Feb 2025 | anterior uveitis, corneal edema, cystoid macular edema | Nicole Fram M.D. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prolensa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05626478 ↗ |
| Modality | Other / unclassified | “Prolensa 0.07% is a NSAID” NCT05626478 ↗ |
| Route | Topical | “being used as a topical drop” NCT05626478 ↗ |